[HTML][HTML] Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection …
B Xie, Q Gao, Y Wang, J Du, Y He - American Journal of …, 2024 - ncbi.nlm.nih.gov
Objective: To analyze the effect of sacubitril-valsartan on left ventricular remodeling and NT-
proBNP in heart failure patients with hypertension and reduced ejection fraction. Method: A …
proBNP in heart failure patients with hypertension and reduced ejection fraction. Method: A …
[HTML][HTML] Sacubitril/valsartan improves left ventricular ejection fraction and reverses cardiac remodeling in Taiwanese patients with heart failure and reduced ejection …
LW Liu, PC Wu, MY Chiu, PF Tu… - Acta Cardiologica Sinica, 2020 - ncbi.nlm.nih.gov
Background The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to
improve outcomes of cardiac death and hospitalization due to heart failure in patients with …
improve outcomes of cardiac death and hospitalization due to heart failure in patients with …
[HTML][HTML] The effect of sacubitril/valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction
F Chen, G Tian, X Bai, J Li… - Annals of Palliative …, 2021 - apm.amegroups.org
Background: The aim of this study was to observe the effect of Sacubitril/Valsartan on
cardiac function and remodeling in patients with heart failure with reduced ejection fraction …
cardiac function and remodeling in patients with heart failure with reduced ejection fraction …
Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan: Comparison between Non …
R Cemin, S Casablanca, L Foco, E Schoepf… - Journal of Clinical …, 2023 - mdpi.com
Sacubitril/valsartan (SV) has been demonstrated to reduce cardiovascular mortality,
hospitalization for heart failure and to induce reverse ventricular remodeling. The present …
hospitalization for heart failure and to induce reverse ventricular remodeling. The present …
Long term metabolic effects of sacubitril/valsartan in non-diabetic and diabetic patients with heart failure reduced ejection fraction: A real life study
G Armentaro, G D'Arrigo, S Miceli, V Cassano… - Frontiers in …, 2022 - frontiersin.org
Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by heart
failure (HF) with reduced ejection fraction (HFrEF). HF and type 2 diabetes mellitus (T2DM) …
failure (HF) with reduced ejection fraction (HFrEF). HF and type 2 diabetes mellitus (T2DM) …
[HTML][HTML] The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: from clinical …
A Mazza, DM Townsend, G Torin, L Schiavon… - Biomedicine & …, 2020 - Elsevier
Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …
[HTML][HTML] Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry
Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …
Effect of Sacubitril/Valsartan on Echocardiographic Parameters and Functional Class in Patients of Heart Failure with Reduced Ejection Fraction
D Kumar, MN Lashari, SA Ali… - Journal of …, 2022 - geographical.go2journals.com
Background: This study sought to determine, in retrospect, the effect of Sacubitril/Valsartan
on the echocardiographic and functional class of ambulatory HFrEF patients taking …
on the echocardiographic and functional class of ambulatory HFrEF patients taking …
The impact of sacrubitril/valsartan on clinical treatment and hs-cTnT and NT-ProBNP serum levels and the left ventricular function in patients with chronic heart failure
Y Gao, C Xing, W Hao, H Zhao, L Wang… - International Heart …, 2020 - jstage.jst.go.jp
Chronic heart failure (CHF) seriously affects the quality of patients' lives. Sacrubitril/valsartan
is a combination angiotensin receptor-neprilysin inhibitor, a new therapeutic drugs to treat …
is a combination angiotensin receptor-neprilysin inhibitor, a new therapeutic drugs to treat …
[HTML][HTML] Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
M Landolfo, F Piani, D Degli Esposti, E Cosentino… - IJC Heart & …, 2020 - Elsevier
Aim Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …
相关搜索
- ventricular remodeling nt probnp
- sacubitril valsartan left ventricle
- sacubitril valsartan heart failure
- sacubitril valsartan ejection fraction
- sacubitril valsartan on cardiac function
- sacubitril valsartan cardiac remodeling
- sacubitril valsartan taiwanese patients
- sacubitril valsartan hypertensive patients
- sacubitril valsartan ventricular function
- sacubitril valsartan meta analysis
- sacubitril valsartan ischemic etiology
- sacubitril valsartan functional class
- sacubitril valsartan nt probnp
- sacubitril valsartan ventricular remodeling
- ejection fraction heart failure
- ejection fraction nt probnp